- CSL Behring is part of an unprecedented industry alliance to develop a potential plasma-derived therapy for treating COVID-19. The alliance will work toward developing one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals at high risk of COVID-19, and to support national governments in their efforts to fight the current pandemic. The collaboration will leverage leading-edge expertise and work that the companies already have underway. Click here for more information.
- Collaborating with the University of Queensland in Australia, whom CSL has a long-standing relationship, to support the development of a COVID-19 vaccine candidate. The company is providing its vaccine development expertise, proprietary technologies and laboratory facilities to optimize the chances of success.
- Donation of Seqirus’ well-established adjuvant technology – MF59® –to multiple entities searching for a COVID-19 vaccine. MF59® is used in the company’s adjuvanted seasonal flu vaccine for the over 65 age group -- one of the most vulnerable populations to COVID-19. Adjuvants can help improve immune response and reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly. In parallel, Seqirus’ remains focused on the production of seasonal influenza vaccines for upcoming season, the importance of which is very much underscored by the COVID-19 pandemic.
- Evaluating potential treatment candidates with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, as part of the company’s previously announced collaboration to investigate new therapies to treat infectious diseases as well as immunological and neurological conditions.
- Engaging with investigators regarding the company’s monoclonal antibodies, including CSL312 and CSL324, to identify treatment candidates from the portfolio that have the potential to treat Diffuse Alveolar Damage – one of the devastating respiratory consequences of COVID-19. These are considered much more experimental approaches, but still potentially very important therapies for people who have suffered the potentially devastating impact of COVID-19.
- Additionally, from the time the corona virus was first identified in Wuhan, China – where CSL Behring has a manufacturing facility – the company has been assisting in the fight against COVID-19 in a number of ways including offering expertise, technologies, equipment and materials on a humanitarian basis.
For the latest information from CSL around the company’s work in the fight against COVID-19, please visit: www.csl.com; www.cslbehring.com; www.seqirus.com.
